Gland Pharma Limited (NSE: GLAND)
India
· Delayed Price · Currency is INR 1,906.00
+14.20 (0.75%)
Sep 6, 2024, 3:29 PM IST
Gland Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2017 |
| Revenue | 58,577 | 56,647 | 36,246 | 44,007 | 34,629 | 26,332 | Upgrade
|
| Revenue Growth (YoY) | 47.31% | 56.29% | -17.64% | 27.08% | 31.51% | 28.81% | Upgrade
|
| Cost of Revenue | 25,112 | 25,539 | 18,595 | 22,494 | 16,097 | 12,155 | Upgrade
|
| Gross Profit | 33,466 | 31,108 | 17,651 | 21,513 | 18,532 | 14,178 | Upgrade
|
| Selling, General & Admin | 13,574 | 12,668 | 4,047 | 3,397 | 3,122 | 2,784 | Upgrade
|
| Other Operating Expenses | 6,856 | 4,895 | 3,271 | 3,009 | 2,385 | 1,823 | Upgrade
|
| Operating Expenses | 24,143 | 21,223 | 8,807 | 7,513 | 6,498 | 5,569 | Upgrade
|
| Operating Income | 9,323 | 9,885 | 8,844 | 14,000 | 12,034 | 8,609 | Upgrade
|
| Interest Expense | -269.01 | -217.9 | -62.87 | -34.02 | -29.11 | -62.51 | Upgrade
|
| Interest & Investment Income | - | 1,506 | 1,794 | 1,386 | 859.49 | 514.86 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 106.05 | 571.45 | 792.05 | 405.26 | 693.11 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,841 | 9.1 | -1.07 | -2.85 | 77.77 | -0.6 | Upgrade
|
| EBT Excluding Unusual Items | 10,895 | 11,288 | 11,146 | 16,142 | 13,348 | 9,754 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 3.48 | 28.48 | 44.89 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 2.49 | -0.81 | -1.78 | 0.24 | 173.93 | Upgrade
|
| Asset Writedown | - | - | -63.32 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -564.61 | - | - | - | Upgrade
|
| Pretax Income | 10,895 | 11,325 | 10,546 | 16,186 | 13,348 | 9,929 | Upgrade
|
| Income Tax Expense | 3,674 | 3,601 | 2,735 | 4,069 | 3,378 | 2,200 | Upgrade
|
| Net Income | 7,221 | 7,725 | 7,810 | 12,117 | 9,970 | 7,729 | Upgrade
|
| Net Income to Common | 7,221 | 7,725 | 7,810 | 12,117 | 9,970 | 7,729 | Upgrade
|
| Net Income Growth | -3.20% | -1.10% | -35.54% | 21.54% | 29.00% | 71.04% | Upgrade
|
| Shares Outstanding (Basic) | 165 | 165 | 165 | 164 | 158 | 155 | Upgrade
|
| Shares Outstanding (Diluted) | 165 | 165 | 165 | 165 | 158 | 155 | Upgrade
|
| Shares Change (YoY) | 0.00% | 0.03% | 0.09% | 3.95% | 2.15% | - | Upgrade
|
| EPS (Basic) | 43.84 | 46.90 | 47.44 | 73.81 | 63.07 | 49.88 | Upgrade
|
| EPS (Diluted) | 43.84 | 46.89 | 47.43 | 73.64 | 62.99 | 49.88 | Upgrade
|
| EPS Growth | -3.20% | -1.14% | -35.59% | 16.91% | 26.29% | 71.05% | Upgrade
|
| Free Cash Flow | - | 6,069 | 1,430 | 2,794 | 3,762 | 5,063 | Upgrade
|
| Free Cash Flow Per Share | - | 36.84 | 8.69 | 16.98 | 23.77 | 32.67 | Upgrade
|
| Dividend Per Share | 20.000 | 20.000 | - | - | - | - | Upgrade
|
| Gross Margin | 57.13% | 54.92% | 48.70% | 48.89% | 53.52% | 53.84% | Upgrade
|
| Operating Margin | 15.92% | 17.45% | 24.40% | 31.81% | 34.75% | 32.69% | Upgrade
|
| Profit Margin | 12.33% | 13.64% | 21.55% | 27.53% | 28.79% | 29.35% | Upgrade
|
| Free Cash Flow Margin | - | 10.71% | 3.95% | 6.35% | 10.86% | 19.23% | Upgrade
|
| EBITDA | 13,264 | 13,138 | 10,310 | 15,102 | 13,020 | 9,553 | Upgrade
|
| EBITDA Margin | 22.64% | 23.19% | 28.44% | 34.32% | 37.60% | 36.28% | Upgrade
|
| D&A For EBITDA | 3,941 | 3,253 | 1,466 | 1,101 | 985.75 | 943.97 | Upgrade
|
| EBIT | 9,323 | 9,885 | 8,844 | 14,000 | 12,034 | 8,609 | Upgrade
|
| EBIT Margin | 15.92% | 17.45% | 24.40% | 31.81% | 34.75% | 32.69% | Upgrade
|
| Effective Tax Rate | 33.72% | 31.79% | 25.94% | 25.14% | 25.31% | 22.16% | Upgrade
|
| Revenue as Reported | 60,419 | 58,350 | 38,651 | 46,246 | 35,977 | 27,724 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.